Protara Therapeutics

TARA-002 Clin1 lymphatic malformations, 2 trials Clin1 bladder cancer, combo Clin0 bladder cancer

Protara Therapeutics is identifying therapies for the treatment of cancer and rare diseases. Protara’s lead candidate, TARA-002, is approved in Japan and Taiwan for multiple oncogenic indications and is being evaluated for non-muscle invasive bladder cancer in the U.S. TARA-002 is a genetically distinct strain of Streptococcus pyogenes that is inactivated while retaining its immune-stimulating properties. If abnormal cancerous tissue is exposed to TARA-002, the abnormal cells are infiltrated and destroyed by the activated immune cells. Protara is also working on an investigational phospholipid substrate replacement therapy, IV Choline Chloride, for the treatment of intestinal failure-associated liver disease.